Akeso’s overseas drug promise fails to slow share decline
The Chinese drugmaker has been under pressure on equity markets since revealing plans for a share placement, overriding positive news for its key cancer therapy Key takeaways: Akeso’s shares have…
The global leap: Chinese biopharma, athletic brands dip toes in global waters
"To out-license drugs is a very handy and clever way for a win-win… but in terms of acquiring the businesses, that's going to be really tough." – Bradley Burgess Key…
A healthy return: drug spin-off nets Keymed up to $320 million
The Chinese biotech set up a separate “NewCo” company for its autoimmune drug, beating the likely proceeds from a conventional out-licensing deal Key Takeaways: International drug rights were transferred to…
InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
Biopharmaceutical company InnoCare Pharma Ltd. (9969.HK; 688428.SH) announcedon Monday that it, along with KeyMed (2162.HK) and their joint venture have signed a licensing deal for one of their products with…
Fast-growing Duoning Biotech seeks winning formula for pricey IPO
The provider of bioprocessing services for the drugs sector has been expanding rapidly via aggressive M&A, backed by big-name investors Key Takeaways: WuXi Biologics is Duoning Biotechnology’s biggest client and…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
9969.HK
688428.SHG
RELATED ARTICLES
-
Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Hengrui makes headway with novel drugs but investors bide their time
1276.HK600276.SHG
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
- Insilico revenue soars above $100 million on AI drug partnerships
